Mid-cap buyers, improved capital raising climate, and reshoring of manufacturing are shaping how much and where biopharmas choose to grow.
What are the best-selling gene therapies on the market? It probably comes as no surprise that Luxturna, Casgevy, and Zolgensma are on the list. But what is number 1? Check out the list to find out.
The past year marked a proverbial inflection point for organoid models designed to uncover biological insights previously unattainable through traditional cell culture experiments or animal models.
Access the latest issue of GEN and browse the archive of back issues when you subscribe to our digital edition.
In the final episode of our special three part series, experts from USP and industry will share first-hand experiences, case studies, and practical insights on how AAV analytics and material controls are evolving. This series will identify common AAV challenges and explore effective solutions across different stages of development.
Register NowTouching Base is the dynamic podcast series from the editors of GEN. Each episode features a rotating case of senior editors—including John Sterling, Kevin Davies, Julianna LeMieux, Alex Phillippidis, Uduak Thomas, Corinna Singleman, and Fay Lin—who delve into emerging stories, exchange ideas, and debate the latest trends in biotech. Additionally, they talk to some of the leading voices in the industry about what’s now and next. Start listening today!
Stay up to date with the lasted episodes of Touching Base by subscribing to the GEN Podcast Newsletter
Copyright © 2026 Sage Publications or its affiliates, licensors, or contributors. All rights reserved, including those for text and data mining and training of large language models, artificial intelligence technologies, or similar technologies.
